WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act:
"The introduction of the PASTEUR Act of 2026 is a vital step forward in confronting one of the most urgent public health threats of our time. Antimicrobial resistance continues to claim millions of lives each year, and patients facing drug-resistant infections are left with fewer and fewer effective treatments. This updated PASTEUR legislation would help to repair the broken marketplace for antimicrobials by enabling a business model centered around the appropriate use of new and novel treatments to address the most threatening infections. We commend these bipartisan leaders in Congress for introducing this critical legislation for innovation and for working to ensure patients will have access to life-saving antimicrobials when they need them most."
###
About BIO
BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.